Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-02006-7
Abstract: Until recently, no effective targeted therapies for FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML) were available in Japan. The FLT3 inhibitor, gilteritinib, was approved in Japan for patients with FLT3mut+ R/R AML based on… read more here.
Keywords: relapsed refractory; gilteritinib; refractory acute; myeloid leukemia ... See more keywords
Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib.
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia research"
DOI: 10.1016/j.leukres.2021.106610
Abstract: Gilteritinib is primarily metabolized via cytochrome P450 (CYP). Therefore, concomitant administration of strong CYP3A4 inducers or inhibitors is not recommended. We evaluated the incidence of gilteritinib-related adverse events (AEs) in 47 patients who received gilteritinib… read more here.
Keywords: fungal diseases; gilteritinib; prophylaxis treatment; gilteritinib triazole ... See more keywords
Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan
Sign Up to like & getrecommendations! Published in 2022 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyac069
Abstract: Abstract Objective Gilteritinib received approval for the treatment of FLT3-mutated relapsed or refractory acute myeloid leukemia in Japan in 2018. In accordance with regulatory requirements, we conducted a multicenter, observational surveillance of gilteritinib use in… read more here.
Keywords: surveillance; flt3 mutated; mutated relapsed; relapsed refractory ... See more keywords
Abstract CT184: Gilteritinib significantly prolongs overall survival in patients withFLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct184
Abstract: Introduction: Gilteritinib is a potent/selective oral inhibitor of FMS-like tyrosine kinase 3 (FLT3). Based upon interim analysis response rates from the ADMIRAL Phase III study of gilteritinib vs salvage chemotherapy (SC) in patients (pts) with… read more here.
Keywords: phase iii; flt3; aml; gilteritinib ... See more keywords
Preclinical Evaluation of Gilteritinib on NPM1-ALK–Driven Anaplastic Large Cell Lymphoma Cells
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Cancer Research"
DOI: 10.1158/1541-7786.mcr-20-0738
Abstract: Anaplastic large cell lymphoma (ALCL) is an aggressive type of non-Hodgkin lymphoma. More than three-fourths of anaplastic lymphoma kinase (ALK)-positive ALCL cases express the nucleophosmin 1 (NPM1)-ALK fusion gene as a result of t(2;5) chromosomal… read more here.
Keywords: kinase; lymphoma; npm1 alk; gilteritinib ... See more keywords
The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-123793
Abstract: Introduction FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations are found in approximately one quarter of acute myeloid leukemia (AML) cases. Its presence results in constitutive activation of the FLT3 receptor tyrosine kinase and… read more here.
Keywords: combination; gilteritinib; cudc 907; flt3 itd ... See more keywords
Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2021005614
Abstract: Drug resistance and relapse are common challenges in acute myeloid leukemia (AML), particularly in an aggressive subset bearing internal tandem duplications (ITD) of the FLT3 receptor (FLT3-ITD+). The tyrosine kinase inhibitor gilteritinib is approved for… read more here.
Keywords: gilteritinib; myeloid leukemia; flt3; acute myeloid ... See more keywords
Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.7003
Abstract: 7003Background: Gilteritinib, a highly selective FLT3/AXL inhibitor, has displayed antileukemic activity in FLT3 mutation-positive (FLT3mut+) relapsed/refractory (R/R) AML in the CHRYSALIS Phase I/... read more here.
Keywords: relapsed refractory; gilteritinib; mutation positive; deep molecular ... See more keywords
A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.tps7068
Abstract: TPS7068Background: Gilteritinib, a highly selective, potent FLT3/AXL inhibitor, showed antileukemic activity with favorable tolerability in a Phase 1/2 trial of FLT3 mutation-positive (FLT3mut+) relapsed/refractory AML. In FLT3mut+ AML cell lines, gilteritinib plus azacitidine (AZA) inhibited… read more here.
Keywords: gilteritinib; phase; newly diagnosed; flt3 mutation ... See more keywords
Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.585151
Abstract: Numerous recurrent genetic mutations are known to occur in acute myeloid leukemia (AML). Among these common mutations, Fms-like tyrosine kinase 3 remains as one of the most frequently mutated genes in AML. We observed apparent… read more here.
Keywords: gilteritinib; myeloid leukemia; acute myeloid; leukemia ... See more keywords